Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 42.51 USD 0.69%
Market Cap: 11.7B USD

EV/EBIT
Enterprise Value to EBIT

13.1
Current
15.9
Median
4.1
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
13.1
=
Enterprise Value
10.7B USD
/
EBIT
814.5m USD
EBIT Growth EV/EBIT to Growth
US
Exelixis Inc
NASDAQ:EXEL
Average EV/EBIT: 18.8
13.1
21%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 136 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -331.3 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
13.4
2-Years Forward
EV/EBIT
11.5
3-Years Forward
EV/EBIT
8.6